ISSN: 0975-3583, 0976-2833 VOL11, ISSUE 01, 2020

Pharmacist Role in Managing Medication Safety in Pediatrics: Challenges and Solutions

Sami Mohammed S. Alsheheri[1*], Mazen Saleh Mohammed Altawyan[2], Bashayer Mohammad Alshehri[3].

[1,2,3]Pharmacist, Ministry of National Guard Health Affairs (MNGHA)

Abstract

Pediatric medication safety presents unique challenges due to children's distinct pharmacokinetic and pharmacodynamic profiles. Medication errors, including dosing inaccuracies, off-label use, and adverse drug reactions (ADRs), are more prevalent in pediatric populations. Pharmacists play a critical role in addressing these challenges by optimizing dosing, preventing ADRs, managing off-label drug use, and educating caregivers. This review explores the pharmacist's role in improving pediatric medication safety, focusing on the complexities of pediatric pharmacotherapy and solutions pharmacists can implement to safeguard pediatric care.

Keywords: Pharmacists, pediatric medication safety, adverse drug reactions, pediatric dosing, off-label drug use, medication reconciliation, pediatric pharmacotherapy

Introduction

Medication safety in pediatric populations is a significant concern, given the physiological differences between children and adults, which require careful attention to dosing, formulation, and administration. Pediatric patients are more vulnerable to medication errors, with studies showing higher rates of adverse drug reactions (ADRs) and dosing inaccuracies in children compared to adults (Kaushal et al., 2001). Pharmacists, as medication experts, are uniquely positioned to mitigate these risks through interventions that optimize medication use, ensure proper dosing, and monitor for potential adverse effects. This review examines the major challenges in pediatric medication safety and outlines how pharmacists can address these challenges through clinical interventions and the implementation of safeguards.

1. Challenges in Pediatric Medication Safety

1.1 Dosing Complexities in Pediatrics

Pediatric dosing is one of the most significant challenges in pediatric pharmacotherapy. Children's drug metabolism, distribution, and excretion differ markedly from adults due to the ongoing development of their hepatic and renal systems (Choonara & Sammons, 2014). Doses must be carefully calculated based on weight, age, body surface area, and maturation of organ function. Failure to accurately calculate doses can result in subtherapeutic dosing, leading to treatment failure, or overdosing, increasing the risk of toxicity.

Weight-based dosing, while essential, is prone to errors. Inaccurate weight measurements or errors in calculation can lead to inappropriate dosing. Additionally, pediatric patients may require adjustments to dosing intervals based on their pharmacokinetics, which vary widely across different age groups (Conroy, 2011).

1.2 Adverse Drug Reactions (ADRs) in Pediatric Patients

Pediatric patients are at higher risk for ADRs due to their developing organ systems, immature drug metabolism, and limited ability to express symptoms (Impicciatore et al., 2001). ADRs can result from inappropriate dosing, drug-drug interactions, or off-label use, which is common in

ISSN: 0975-3583, 0976-2833 VOL11, ISSUE 01, 2020

pediatric care. Younger children, especially neonates, are particularly vulnerable to the toxic effects of certain medications due to their limited ability to metabolize and eliminate drugs effectively (Ghaleb et al., 2010).

Monitoring for ADRs in pediatric patients is often complicated by communication barriers, as younger children may not be able to describe their symptoms accurately. Consequently, healthcare providers and caregivers must remain vigilant to detect subtle signs of drug toxicity.

1.3 Off-Label and Unlicensed Drug Use

Off-label drug use is prevalent in pediatric care because many medications lack pediatric-specific labeling due to the ethical and logistical challenges of conducting clinical trials in children (Conroy et al., 2000). Off-label prescribing involves administering drugs that have not been adequately studied for safety, efficacy, or appropriate dosing in pediatric patients, increasing the risk of ADRs and therapeutic failure. Approximately 50-90% of drugs used in neonatal and pediatric intensive care units are prescribed off-label, underscoring the need for careful monitoring (Conroy, 2011).

1.4 Formulation and Administration Challenges

Many drugs used in pediatric care are not available in child-friendly formulations, such as liquids or chewable tablets. Pharmacists and healthcare providers often manipulate adult formulations by crushing tablets or splitting capsules to create appropriate doses for children. These practices can lead to dosing inaccuracies and affect the stability or bioavailability of the medication (Richey et al., 2013).

Additionally, liquid formulations, which are more common in pediatrics, are susceptible to dosing errors if caregivers use imprecise measuring devices. Studies have shown that many caregivers administer incorrect doses when using household spoons, which can result in significant under- or overdosing (Yin et al., 2010).

2. Pharmacists' Role in Enhancing Pediatric Medication Safety

Pharmacists are central to improving pediatric medication safety. Their expertise in drug therapy allows them to intervene at various points in the medication-use process to optimize dosing, prevent ADRs, and ensure safe administration. The following sections outline specific ways pharmacists contribute to pediatric medication safety.

2.1 Dosing Optimization and Error Prevention

Pharmacists play a crucial role in ensuring that pediatric patients receive accurate doses of medications. They are responsible for verifying dosing calculations based on weight or body surface area, adjusting doses according to renal and hepatic function, and ensuring that the prescribed medication is appropriate for the child’s age and condition (Kaushal et al., 2001).

In hospital settings, pharmacists can integrate clinical decision support tools into computerized physician order entry (CPOE) systems, which automatically calculate pediatric doses and flag potential dosing errors (Pham et al., 2012). These systems reduce the likelihood of manual calculation errors and ensure that pediatric patients receive doses within the recommended therapeutic range.

2.2 Medication Reconciliation

Medication reconciliation is essential in pediatric care, particularly during transitions of care such as hospital admissions or discharges. Pharmacists are responsible for reviewing and updating medication lists to ensure that all medications are accurately documented, and potential discrepancies are identified (Lindell-Osuagwu et al., 2012). Reconciliation is particularly important for pediatric patients with chronic conditions or complex medication regimens, where the risk of drug interactions and duplicate therapies is high.

ISSN: 0975-3583, 0976-2833 VOL11, ISSUE 01, 2020

Pharmacists should work closely with pediatricians and other healthcare providers to ensure that medication regimens are safe and effective, and that caregivers are informed about proper administration techniques and potential side effects.

2.3 Adverse Drug Reaction Monitoring

Pharmacists are well-positioned to monitor pediatric patients for ADRs, particularly in hospital settings where polypharmacy is common. By conducting regular medication reviews and monitoring drug levels in children on high-risk medications, such as anticonvulsants or antibiotics, pharmacists can detect early signs of ADRs and recommend adjustments to therapy (Aagaard et al., 2010).

Pharmacists should also educate caregivers and healthcare providers on how to recognize and report potential ADRs in pediatric patients. Pharmacovigilance programs, which involve tracking and reporting ADRs, are particularly important in pediatric care due to the frequent off-label use of medications.

2.4 Education for Caregivers and Healthcare Providers

Pharmacists play a key role in educating caregivers and healthcare providers about safe medication use in pediatric patients. They can provide clear instructions on dosing, administration techniques, and the use of appropriate measuring devices, such as oral syringes or calibrated dosing cups, to prevent dosing errors at home (Yin et al., 2010).

Pharmacists should also offer guidance to healthcare providers on pediatric pharmacotherapy, including appropriate dosing adjustments, drug interactions, and strategies for minimizing the risk of ADRs. Through education, pharmacists help ensure that both caregivers and healthcare providers have the knowledge and tools they need to administer medications safely.

2.5 Advocacy for Pediatric-Specific Formulations

Pharmacists are essential advocates for the development and availability of pediatric-specific formulations. They can work with pharmaceutical companies, regulatory agencies, and healthcare organizations to promote the creation of age-appropriate formulations, such as liquids, chewable tablets, or dissolvable films, that improve medication adherence and safety in children (Richey et al., 2013).

In situations where pediatric formulations are unavailable, pharmacists may need to compound medications by adjusting adult formulations to suit pediatric needs. Compounding requires meticulous attention to accuracy and stability to ensure that the medication remains effective and safe for the child.

3. Implementing Safeguards in Pediatric Care

Pharmacists can implement several safeguards to enhance pediatric medication safety. These include the use of clinical decision support tools, adherence to pediatric-specific dosing guidelines, and the development of robust monitoring systems for adverse events.

3.1 Clinical Decision Support Tools

The use of technology, such as electronic health records (EHRs) and CPOE systems with integrated pediatric dosing algorithms, can significantly reduce the risk of dosing errors. Pharmacists can collaborate with healthcare institutions to ensure that these systems are designed to meet the specific needs of pediatric patients, including weight-based dosing calculations and alerts for potential drug interactions (Pham et al., 2012).

3.2 Pediatric Dosing Guidelines

Pharmacists should adhere to pediatric-specific dosing guidelines and consult reliable references, such as the British National Formulary for Children (BNFC) or the American Academy of

ISSN: 0975-3583, 0976-2833 VOL11, ISSUE 01, 2020

Pediatrics (AAP) guidelines, when reviewing pediatric prescriptions (Conroy, 2011). These guidelines provide evidence-based recommendations for pediatric dosing and can help ensure that children receive safe and effective therapies.

3.3 Monitoring Systems for Adverse Drug Reactions

Pharmacists should actively participate in ADR monitoring and reporting systems, which are critical for improving pediatric medication safety. By tracking ADRs in pediatric patients, pharmacists can identify trends and recommend changes to prescribing practices or medication regimens to reduce the risk of adverse events (Impicciatore et al., 2001).

Conclusion

Pediatric medication safety presents significant challenges due to the complexities of dosing, the prevalence of off-label drug use, and the increased risk of ADRs in this population. Pharmacists are uniquely positioned to address these challenges by optimizing dosing, conducting medication reconciliation, monitoring for ADRs, and educating caregivers and healthcare providers. Through the implementation of clinical decision support tools, adherence to pediatric-specific dosing guidelines, and advocacy for age-appropriate formulations, pharmacists can significantly improve medication safety for pediatric patients.

References

1. Aagaard, L., Hansen, E. H., & Garbe, E. (2010). Adverse drug reactions in children: A retrospective analysis of spontaneous reports to the Danish Medicines Agency from 1998 to 2007. *Drug Safety*, 33(4), 327-339. doi.org/10.2165/11319310-000000000-00000
2. Choonara, I., & Sammons, H. (2014). Paediatric clinical pharmacology: What is it, and why is it important? *British Journal of Clinical Pharmacology*, 79(1), 33-39. doi.org/10.1111/bcp.12323
3. Conroy, S. (2011). Unlicensed and off-label drug use in neonates. *British Journal of Clinical Pharmacology*, 71(5), 659-667. doi.org/10.1111/j.1365-2125.2010.03899.x
4. Conroy, S., McIntyre, J., & Choonara, I. (2000). Unlicensed and off-label drug use in neonates. *Archives of Disease in Childhood. Fetal and Neonatal Edition*, 82(3), F183-F185. doi.org/10.1136/fn.82.3.F183
5. Ghaleb, M. A., Barber, N., Franklin, B. D., et al. (2010). Systematic review of medication errors in pediatric patients. *Annals of Pharmacotherapy*, 44(10), 1872-1881. doi.org/10.1345/aph.1P658
6. Impicciatore, P., Choonara, I., Clarkson, A., Provasi, D., Pandolfini, C., & Bonati, M. (2001). Incidence of adverse drug reactions in pediatric in/out-patients: A systematic review and meta-analysis of prospective studies. *British Journal of Clinical Pharmacology*, 52(1), 77-83. doi.org/10.1046/j.0306-5251.2001.01380.x
7. Kaushal, R., Bates, D. W., Landrigan, C., et al. (2001). Medication errors and adverse drug events in pediatric inpatients. *JAMA*, 285(16), 2114-2120. doi.org/10.1001/jama.285.16.2114
8. Lindell-Osuagwu, L., Korhonen, M. J., Saano, S., & Laine, K. (2012). Off-label and unlicensed drug prescribing in three pediatric wards in Finland and review of the international literature. *Journal of Clinical Pharmacy and Therapeutics*, 37(5), 528-532. doi.org/10.1111/j.1365-2710.2011.01338.x

ISSN: 0975-3583, 0976-2833 VOL11, ISSUE 01, 2020

9. Pham, J. C., Aswani, M. S., Rosen, M., et al. (2012). Reducing medical errors and adverse events. *Annual Review of Medicine*, 63, 447-463. doi.org/10.1146/annurev-med-061410-121352
10. Richey, R. H., Hughes, C., Craig, J. V., et al. (2013). A systematic review of the use of dosage forms that require manipulation to provide doses to children. *International Journal of Pharmaceutics*, 457(1), 310-323. doi.org/10.1016/j.ijpharm.2013.09.040
11. Yin, H. S., Dreyer, B. P., Ugboaja, D. C., et al. (2010). Unit of measurement used and parent medication dosing errors. *Pediatrics*, 125(2), 291-297. doi.org/10.1542/peds.2009-1145